Podium to Practice: Chicago 2025 – GU: Gut-associated checkpoint in mRCC

Podium to Practice: Chicago 2025 – GU: Gut-associated checkpoint in mRCC

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sebastien Hotte

Icon Chair Speaker

Speakers

Dr. Nimira Alimohamed

Dr. Maria Jiang

Studies / Trials Discussed

4512 – Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.

This program has been made possible through unrestricted support from Ipsen.

Studies/trials discussed:

4512 – Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
Tagged